# Novo Nordisk

> Novo Nordisk is a VC fund in Bagsværd backing Biotechnology and Health Care. See 20 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Bagsværd, Denmark
- Total investments: 20
- Last investment: May 2026
- Lead investor: 45%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/novo-nordisk
- X (Twitter): http://twitter.com/novonordisk
- Website: http://www.novonordisk.com/
- Facebook: http://www.facebook.com/novonordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.

## Contacts

5 contacts available for Novo Nordisk. Shizune tracks 12 team members at Novo Nordisk. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/novonordisk?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5M–$17M |
| Series C | $16M–$57M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 65% |
| Health Care | 10 | 50% |
| Therapeutics | 5 | 25% |
| Pharmaceutical | 4 | 20% |
| Medical | 3 | 15% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 15% |
| Series C | 3 | 15% |
| Corporate Round | 3 | 15% |
| Seed | 2 | 10% |
| Series B | 2 | 10% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 45% |
| Denmark | 2 | 10% |
| Canada | 1 | 5% |
| France | 1 | 5% |
| Belgium | 1 | 5% |

7 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Adela Michea | Director of Portfolio, Communication & Organisational Readiness, Development External Innovation | 1 | https://shizune.co/investors/profile/adela-michea |
| Christian Wenzel Tornøe | Principal Scientist | 0 | https://shizune.co/investors/profile/christian-wenzel-torn%C3%B8e |
| Greg Jones | Vice President, Legal Affairs | 0 | https://shizune.co/investors/profile/greg-jones-6 |
| Henrik Gürtler | Corporate Vice President of Human Resource Development | 0 | https://shizune.co/investors/profile/henrik-grtler |
| Jeppe Christiansen | Vice Chairman of the Board of Directors | 3 | https://shizune.co/investors/profile/jeppe-christiansen |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cellular Intelligence | Somite is a mission to transform the lives of millions of people by leveraging AI to produce human tissue for cell-based therapies. |  | Corporate Round | May 11, 2026 |  |
| Proton HeartPet | Proton HeartPet is the company in the field of pet intelligent medical care. |  | Angel | Mar 23, 2026 |  |
| Cantoni Therapeutics |  |  | Grant | Sep 16, 2025 |  |
| Aspect Biosystems | Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development andcommercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic. | $115M | Series B | Jan 08, 2025 |  |
| Eikonizo Therapeutics | Eikonizo is developing life-changing treatments by producing brain-penetrant small compounds and utilizing in vivo target engagement approaches to speed therapeutic discovery. |  | Corporate Round | Dec 10, 2024 |  |
| Tanai Therapeutics | Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications. | $3.5M | Seed | Sep 19, 2024 |  |
| ElevateBio | ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines.The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elementsthat translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017. | $401M | Series D | May 24, 2023 |  |
| Aspect Biosystems | Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development andcommercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic. |  | Convertible Note | Apr 12, 2023 |  |
| The Sabi | The Sabi is a community-driven holistic beauty brand that empowers women from conception to postpartum, menopause, and everyday hormonal woes. | $163.8K | Pre-Seed | Apr 06, 2023 |  |
| Amalgam Rx | Amalgam Rx is the leader in bringing providers, life sciences, and digital solutions together. For more than 15 years, our team has been reimagining care delivery and creating lasting change across the chronic care ecosystem. Working in partnership with many of the world’s leading life sciences companies, Amalgam Rx has built an innovative platformfor rapidly developing and scaling digital solutions — delivered through a wide variety of business models. Our proven end-to-end methodology enables the entire life cycle from R&D to commercialization. Amalgam’s solutions have generated more than 5 billion RWE data points utilized by patients and providers on three continents. For more information on how Amalgam Rx’s regulated, clinically validated technologies bring patients and providers closer together, reduce costs for payers, and unlock sustained value for partners, visit amalgamrx.com. | $17.4M | Series A | Jan 03, 2023 |  |

10 of 20 investments shown.

## Co-investors
- [ArrowMark Partners](https://shizune.co/investors/profile/arrowpoint-partners) — VC Fund, 2 deals together
- [Ace Capital Partners](https://shizune.co/investors/profile/ace-capital-partners) — VC Fund, 1 deal together
- [Aeris Capital](https://shizune.co/investors/profile/aeris-capital) — VC Fund, 1 deal together
- [Akka Venture](https://shizune.co/investors/profile/akka-venture) — VC Fund, 1 deal together
- [Ardian](https://shizune.co/investors/profile/ardian) — VC Fund, 1 deal together
- [Auriga Partners](https://shizune.co/investors/profile/auriga-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Denmark](https://shizune.co/investors/biotechnology-investors-denmark)
- [Biotechnology VC Funds in Denmark](https://shizune.co/investors/biotechnology-vc-funds-denmark)
- [Biotech VC Funds in Denmark](https://shizune.co/investors/biotech-vc-funds-denmark)
- [Agriculture (agtech) Investors in Denmark](https://shizune.co/investors/agriculture-agtech-investors-denmark)
- [Health Care Investors in Denmark](https://shizune.co/investors/health-care-investors-denmark)
- [Health Care VC Funds in Denmark](https://shizune.co/investors/health-care-vc-funds-denmark)

## FAQ

### What does Novo Nordisk invest in?

Novo Nordisk invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series C stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Novo Nordisk's check size?

Novo Nordisk typically joins rounds of $5M–$17M at Series A and $16M–$57M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Novo Nordisk participates in.

### How do I contact Novo Nordisk?

Public channels for Novo Nordisk include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Novo Nordisk?

The team at Novo Nordisk includes Adela Michea (Director of Portfolio, Communication & Organisational Readiness, Development External Innovation), Christian Wenzel Tornøe (Principal Scientist) and Greg Jones (Vice President, Legal Affairs), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co